Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from Lupin Limited ( (IN:LUPIN) ).
Lupin Limited announced that it has received the Establishment Inspection Report (EIR) from the U.S. FDA for its Aurangabad facility after a product-specific Pre-Approval Inspection. This achievement highlights Lupin’s dedication to maintaining high standards of quality and compliance, reinforcing its reputation as a trusted provider of healthcare solutions globally. The receipt of the EIR is a significant milestone for Lupin, potentially enhancing its operational capabilities and market positioning, particularly in the U.S., which is a critical market for the company.
More about Lupin Limited
Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with a presence in over 100 markets. The company specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Lupin holds a strong market position in India and the U.S. across various therapy areas such as respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women’s health. With 15 manufacturing sites and 7 research centers globally, Lupin is committed to improving patient health outcomes through its subsidiaries.
Average Trading Volume: 21,112
Technical Sentiment Signal: Buy
Current Market Cap: 907.7B INR
Learn more about LUPIN stock on TipRanks’ Stock Analysis page.